The case for & against
Bull & Bear analysis
Evotec SE (NASDAQ: EVO) is a prominent player in the biotechnology sector, specializing in drug discovery and development services for pharmaceutical and biotech companies. The company offers integrated scientific solutions spanning early drug discovery through to late-stage development and commercialization. Evotec operates under a strategic partnership model, leveraging cutting-edge technologies and experienced personnel to drive profitability and growth. In recent times, it is focused on enhancing its capabilities through the Horizon Business Transformation initiative, aiming to navigate a challenging market landscape and improve financial performance.
Bull says
- ↑Horizon initiative targets €60 M annual cost savings via 60% capex and R&D cuts.
- ↑Just Evotec Biologics revenue up 104% YoY to €59.4 M in Q4 2025.
- ↑Sandoz partnership slated for over €650 M in total payments.
- ↑Gradual biotech market recovery expected to improve DMPD sector activity.
- ↑Strong dividend yield and positive profitability underpin sustainable cash generation.
- ↑Management expects first Horizon benefits in H2 2026, boosting profitability.
Bear says
- ↓DMPD segment revenue fell 11% in Q1 2025 amid funding headwinds.
- ↓Q1 2026 revenue dropped 21.7% YoY to €156.6 M, reflecting license-payment pullback.
- ↓Negative earnings yield and poor revisions reflect bleak profitability outlook.
- ↓High stock volatility and short interest underscore market skepticism.
- ↓Horizon restructuring risks operational disruption amid workforce cuts.
- ↓Net debt rose to €107 M, raising leverage and refinancing concerns.
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- In addition, we have started execution of the Horizon Plan, which is designed to put Evotech on a path towards sustainable growth and greater profitability while navigating a still challenging market environment.
- we continue to expect structural run rate savings of approximately 75 million euro by the end of 2027, with around 20 to 30% of these savings expected to materialize in 2026.
- we expect to begin seeing impacts in the latter half of 2026, with 20 to 30% of the estimated structural run rate savings of €75 million being realized in 2026.
Bear points
- the quarter's major business highlights were characterized by a strong operational focus, important leadership enhancements, and positive commercial indicators that support the next phase of our transformation.
- adjusted group ABDA was negative 21.9 million euros. As mentioned before, this was primarily due to a challenging prior year comparison based on a one-off license sale in that quarter.
- As expected, our financial results in the first quarter of 2026 fell significantly compared with the same quarter last year due to a number of factors that we do not expect to persist into the rest of this year.